(Q36065956)

12 August 2017

1 reference

title

Antisense approaches for inhibiting respiratory syncytial virus (English)

1 reference

12 August 2017

Hagen Cramer

1

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 February 2005

1 reference

Expert Opinion on Biological Therapy

12 August 2017

published in

1 reference

12 August 2017

volume

5

1 reference

12 August 2017

issue

2

1 reference

12 August 2017

page(s)

207-220

1 reference

Respiratory syncytial virus infections in children and adults

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Nosocomial respiratory syncytial virus infections: the "Cold War" has not ended

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Respiratory syncytial virus (RSV) disease and prospects for its control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Respiratory syncytial virus infection in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Mortality associated with influenza and respiratory syncytial virus in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Contribution of influenza and respiratory syncytial virus to community cases of influenza-like illness: an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Respiratory syncytial virus infections--an underdiagnosed entity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Respiratory syncytial virus pneumonia among the elderly: an assessment of disease burden

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Respiratory syncytial virus infections in previously healthy working adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Respiratory syncytial virus infections in infants: Quantitation and duration of shedding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Treatment of RSV pneumonia in adults--evidence of ribavirin effectiveness?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Preventive and therapeutic strategies for respiratory syncytial virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Respiratory syncytial virus infection: clinical features, management, and prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Management of respiratory syncytial virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Early ribavarin treatment of bronchiolitis: effect on long-term respiratory morbidity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Ribavirin in ventilated respiratory syncytial virus bronchiolitis. A randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Ribavirin: a clinical overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Ribavirin: An antiviral agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Ribavirin causes error catastrophe during Hantaan virus replication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

RNA virus error catastrophe: direct molecular test by using ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Lack of sensitivity of rapid antigen tests for the diagnosis of respiratory syncytial virus infection in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Evaluation of the QuickLab RSV test, a new rapid lateral-flow immunoassay for detection of respiratory syncytial virus antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

In search of a small-molecule inhibitor for respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Respiratory syncytial virus: recent progress towards the discovery of effective prophylactic and therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Inhalation efficacy of RFI-641 in an African green monkey model of RSV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

RSV entry inhibitors block F-protein mediated fusion with model membranes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

RFI-641 inhibits entry of respiratory syncytial virus via interactions with fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

The discovery of RFI-641 as a potent and selective inhibitor of the respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Pharmacokinetics of a benzodithiin (RD3-0028) following aerosol treatment in rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Mechanism of selective inhibition of respiratory syncytial virus by a benzodithiin compound (RD3-0028).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Mouse model of respiratory syncytial virus infection to evaluate antiviral activity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Substituted benzimidazoles with nanomolar activity against respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Orally active fusion inhibitor of respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Oral efficacy of a respiratory syncytial virus inhibitor in rodent models of infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Targeting a binding pocket within the trimer-of-hairpins: small-molecule inhibition of viral fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Synthesis of azole nucleoside 5'-monophosphate mimics (P1Ms) and their inhibitory properties of IMP dehydrogenases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Toxicity and antiviral activity of LY253963 against respiratory syncytial and parainfluenza type 3 viruses in tissue culture and in cotton rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

VX-497: a novel, selective IMPDH inhibitor and immunosuppressive agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Comparison of corticosteroids for treatment of respiratory syncytial virus bronchiolitis and pneumonia in cotton rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Systemic corticosteroids in infant bronchiolitis: A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Prospects for a respiratory syncytial virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Role of chemokines in respiratory syncytial virus disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

RSV-induced immunopathology: dynamic interplay between the virus and host immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Interactions between RSV infection, asthma, and atopy: unraveling the complexities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Gene expression of nonsegmented negative strand RNA viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Nucleotide sequences for the gene junctions of human respiratory syncytial virus reveal distinctive features of intergenic structure and gene order

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Background of the antisense oligonucleotide approach to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Antisense therapeutics: from theory to clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Applying antisense technology: Affinitak and other antisense oligonucleotides in clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Inhibition of respiratory syncytial virus replication by antisense oligodeoxyribonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Blocking intercellular adhesion molecule-1 on human epithelial cells decreases respiratory syncytial virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Prediction of Clinical Responses in a Simulated Phase III Trial of Crohn's Patients Administered the Antisense Phosphorothioate Oligonucleotide ISIS 2302: Comparison of Proposed Dosing Regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Targeting RNA for degradation with a (2'-5')oligoadenylate-antisense chimera

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Potent inhibition of respiratory syncytial virus replication using a 2-5A-antisense chimera targeted to signals within the virus genomic RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

2'-5' Oligoadenylate synthetase plays a critical role in interferon-gamma inhibition of respiratory syncytial virus infection of human epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Targeting RNA decay with 2',5' oligoadenylate-antisense in respiratory syncytial virus-infected cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

2-5A-DNA conjugate inhibition of respiratory syncytial virus replication: effects of oligonucleotide structure modifications and RNA target site selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Targeted therapy of respiratory syncytial virus in African green monkeys by intranasally administered 2-5A antisense

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Recruiting the 2-5A system for antisense therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

5'-O-Monophosphoryladenylyl(2' goes to 5')adenylyl(2' goes to 5')adenosine is an antagonist of the action of 5'-O-triphosphoryladenylyl-(2' goes to 5')adenylyl(2' goes to 5')adenosine and double-stranded RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Potent inhibition of respiratory syncytial virus by combination treatment with 2-5A antisense and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Evaluation of the toxicity and antiviral activity of carbocyclic 3-deazaadenosine against respiratory syncytial and parainfluenza type 3 viruses in tissue culture and in cotton rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Further studies with short duration ribavirin aerosol for the treatment of influenza virus infection in mice and respiratory syncytial virus infection in cotton rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Biochemistry and clinical applications of ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Efficacy of high dose-short duration ribavirin aerosol in the treatment of respiratory syncytial virus infected cotton rats and influenza B virus infected mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

Blockage of NF-kappa B signaling by selective ablation of an mRNA target by 2-5A antisense chimeras

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

DNA antisense therapy for asthma in an animal model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.207

21 January 2018

Identifiers

DOI

10.1517/14712598.5.2.207

1 reference

12 August 2017

1 reference